Protocol No
ECOG-EA9181-ALL
Principal Investigator
Ehab Atallah
Phase
III
Summary
This study is being done to determine what effects (good or bad) using the combination of potent TKI, steroids and blinatumomab versus treatment with steroids, TKI and chemotherapy. This investigational therapy will be added to what has traditionally been used to treat this specific sub-type of ALL. Studies are being done in ALL and other blood cancers with blinatumomab.
Description
Steroids plus TKI with Blinatumomab or Chemo for Newly Diagnosed BCR-ABL Positive ALL in Adults
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
ClinicalTrials.gov